Sign in

    Helen Brand

    Director and Equity Research Analyst at UBS Group AG

    Helen Brand is a Director and Equity Research Analyst at UBS Group AG, specializing in European healthcare and pharmaceutical companies. She covers major firms such as GlaxoSmithKline, AstraZeneca, and Sanofi, providing in-depth analysis and actionable investment recommendations with a proven track record reflected by a high success rate and average returns exceeding market indices on platforms like TipRanks. Helen began her career in equity research in the late 2000s, previously holding analyst positions at other leading financial institutions before joining UBS in 2019. She holds recognized credentials including FINRA registration and Series 7 & 63 securities licenses, and has been cited for her clarity in earnings forecasts and sector insights.

    Helen Brand's questions to COMPAGNIE FINANCIERE RICHEMONT AG /FI (CFRUY) leadership

    Helen Brand's questions to COMPAGNIE FINANCIERE RICHEMONT AG /FI (CFRUY) leadership • FY 2017

    Question

    Helen Brand of UBS inquired about Richemont's digital strategy, including online sales on platforms like NET-A-PORTER and the use of social media, and asked for guidance on operating expense plans for the upcoming year.

    Answer

    Chairman Johann Rupert rejected the premise of needing to "catch up" digitally, citing Richemont's long-standing involvement with NET-A-PORTER and advanced integrated systems. He emphasized the goal is to be ahead of the curve in a rapidly evolving omni-channel environment. He and CFO Gary Saage firmly declined to provide specific forward-looking guidance on operating expenses, stating that spending will be allocated dynamically to what is deemed important and urgent.

    Ask Fintool Equity Research AI